Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: Ted M who wrote (61247)	2/7/2007 9:22:02 AM
From: Suma	Read Replies (2) \| Respond to of 120406

Does VRS,TO have a pink sheet symbol. Thanks

To: Ted M who wrote (61247)	5/14/2007 11:55:14 AM
From: ACAN	Respond to of 120406

MIR.V showing some strength off an unwarranted bottom, now .155

To: Ted M who wrote (61247)	11/15/2007 3:03:41 PM
From: ACAN	Respond to of 120406

[MIR.V] [MMIRF] MedMira's HIV Test Approved Under USAID Initiative - Allows for International Purchase as Part of US Presidential Plan for AIDS Relief Thursday November 15, 8:35 am ET HALIFAX, Nov. 15 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a global market leader in premium rapid diagnostic solutions, announced today that its Reveal G3 Rapid HIV-1 Antibody Test ("Reveal G3") has been approved for purchase by the U.S. Agency for International Development ("USAID"), resulting in the placement of Reveal G3 on USAID's rapid HIV test procurement list. USAID's office of HIV/AIDS is responsible for leading the Agency's efforts within the President's Emergency Plan for AIDS Relief ("PEPFAR"); a $15 billion multifaceted approach to combating HIV and AIDS in over 100 countries, with particular emphasis on fifteen focus countries in Africa, Asia and Latin America. MedMira's inclusion on this procurement list enables Reveal G3 to be purchased for USAID-funded projects, and permits countries receiving USAID funding to purchase Reveal G3 under the PEPFAR program

To: Ted M who wrote (61247)	3/13/2008 11:16:53 AM
From: ACAN	Respond to of 120406

[MIR.V] currently a bargain at .36 MedMira Files Patent Application for Next Generation Rapid Test HALIFAX, Mar 13, 2008 (Canada NewsWire via COMTEX News Network) -- Company Focuses on Simplicity and Quality in Advancing Rapid Platform MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a global market leader in premium rapid diagnostic solutions, announced today that it has filed a patent application with the United States Patent Office for its new rapid test platform. MedMira's research & development team has been working on a next generation, rapid test based on the company's patented flow-through diagnostic technology. This next generation rapid test is built on the key quality and performance attributes that have enabled MedMira's rapid HIV and HIV/Hepatitis combination tests to obtain regulatory approvals from the most stringent regulatory authorities in the world, including United States, Canada, China, India, Russia, and Europe. "Our new test platform provides the user with an even simpler, user-friendly testing procedure than we currently offer in our rapid tests, without sacrificing the high quality and consistent performance that MedMira has built its reputation on," said Dr. Neeraj Vats, Vice President of Technology & Intellectual Property, MedMira Inc. "The new test platform makes it possible to perform a rapid, flow-through test in just two easy steps, and exhibits the high sensitivity and specificity for which MedMira tests are known the world over." Dr. Vats continued, "Our new rapid test platform will have broad applications across a wide range of diagnostic fields, including the diagnosis of infectious diseases such as HIV, hepatitis, and influenza, as well as new health epidemics that will emerge in the future. The platform will also be able to aid in the diagnosis or monitoring of non-infectious conditions such as cancer and cardiovascular disease." As healthcare providers and public health authorities around the world take greater steps to combat epidemics like HIV and Hepatitis, the demand for advanced rapid tests will continue to grow. MedMira's rapid tests are designed for performance in any type of testing setting, from the laboratory to point of care to consumer products for self-testing. While healthcare budgets and resources are constantly under pressure, and with self-testing becoming accepted in various markets; MedMira will be ready to meet the growing demand with this next generation rapid test platform. "MedMira is built on innovation and its ability to understand the future needs of healthcare providers and patients. As market demands increase for consumer products for self-testing, MedMira will be ready with this next generation test, placing the power of rapid testing in the hands of patients, enabling them to monitor and maintain their health wherever and whenever it is most convenient and comfortable," said Dr. Vats.